JP3818483B2 - Oral melanin production inhibiting composition and food having whitening effect - Google Patents

Oral melanin production inhibiting composition and food having whitening effect Download PDF

Info

Publication number
JP3818483B2
JP3818483B2 JP21931399A JP21931399A JP3818483B2 JP 3818483 B2 JP3818483 B2 JP 3818483B2 JP 21931399 A JP21931399 A JP 21931399A JP 21931399 A JP21931399 A JP 21931399A JP 3818483 B2 JP3818483 B2 JP 3818483B2
Authority
JP
Japan
Prior art keywords
extract
whitening
whitening effect
oral
rose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP21931399A
Other languages
Japanese (ja)
Other versions
JP2001048801A5 (en
JP2001048801A (en
Inventor
高樹 阿部
敦子 桑田
隆志 松末
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOF Corp
Original Assignee
NOF Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NOF Corp filed Critical NOF Corp
Priority to JP21931399A priority Critical patent/JP3818483B2/en
Publication of JP2001048801A publication Critical patent/JP2001048801A/en
Publication of JP2001048801A5 publication Critical patent/JP2001048801A5/en
Application granted granted Critical
Publication of JP3818483B2 publication Critical patent/JP3818483B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【0001】
【発明の属する技術分野】
本発明は、バラあるいはキクの抽出エキスを有効成分として含有する経口用メラニン生成抑制組成物及び該組成物を含有する食品に関する。
【0002】
【従来の技術】
一般に、日焼けによる色黒、シミ、ソバカス等は、黒褐色無定形の色素であるメラニンの生成により生ずるものである。また、生まれつき肌が色黒の人も、メラニン生成度の大きい体質の人と考えられる。
生理的に、皮膚にメラニンが生成する原因は、未だ完全には解明されてはいないが、その成因の一つとして、皮膚が紫外線などの外的刺激を受けると、皮膚のメラニンを産生するメラノサイトの細胞内に存在するチロシナーゼ(チロシン酸化酵素)が活性化し、タンパク質構成アミノ酸の一種であるチロシンが酸化されて生成する機構が解明されている。体質的に色黒の人は、このチロシナーゼの活性化が鋭敏な体質と推定することができる。
このことから、メラニン生成に関与するチロシナーゼの活性を抑制することにより肌を白くする効果が期待されるため、チロシナーゼ活性抑制成分の化粧料への配合が提唱されてきた。
このような観点から、シミ・ソバカスの防止剤として、紫外線吸収剤の他に、アスコルビン酸やハイドロキノン誘導体等の還元剤、コウジ酸やリノール酸等のチロシナーゼ阻害剤(特開昭63−284109号公報、特開平1−85907号公報を参照)、カテコール配糖体等を主成分とする美白剤(特開平4−1115号公報を参照)、フラボノイドを主成分とする美白剤(特開昭55−92305号公報を参照)、イソフエルラ酸を主成分とする美白剤(特開昭62−10312号公報を参照)、アゼライン酸を主成分とする美白剤(特開昭61−85307号公報を参照)等が開発されてきた。
一方、バラ科植物由来の生薬の抽出エキスが配合された美白化粧料(特開平3−127714号公報を参照)、バラ科植物の抽出エキスが配合された美白化粧料(特開平9−227353号公報を参照)等が開発されているが、これらはいずれも皮膚外用剤であり、経口用の美白用メラニン生成抑制組成物は知られていない。
【0003】
【発明が解決しようとする課題】
前記の従来技術の美白剤は、いずれも皮膚外用剤であり、皮膚外用剤の場合、美白効果は塗布した局所的な部分のみの効果しか期待できないため、全身的美白効果を必要とする人には、不十分であった。さらに、美容上、特に関心の高い顔等の部分的美白効果を希望する人の場合も、発汗や物理的摩擦作用によって効果が低下あるいは消失することがあり、短時間毎に塗布しなければならないので不便であった。
本発明は、このような現状において、常用しても副作用がなく、全身的美白効果があり、発汗及び摩擦によって美白作用効果が低下しない美白手段を提供することを目的とするものである。
【0004】
【課題を解決するための手段】
本発明者らは、従来の美白剤の欠点は、皮膚に塗布するために起こる欠点であることに着目して、経口的に服用して、美白効果があるものを見いだせば、これらの欠点は同時に解決できることに着目して、従来より経皮的に効果のあるものの中から、服用しても毒性がなく、服用しても有効に作用効果が存在するものを鋭意研究した結果、バラ及びキクの抽出エキスを経口的に摂取しても顕著なメラニン産生抑制作用を持つことを発見し、この知見に基づき本発明を完成させるに至った。
すなわち、本発明は、バラ(ただし、タイワンノイバラを除く)の抽出液を濃縮した乾燥粉末組成物を有効成分として含有する経口用メラニン生成抑制組成物を提供するものである。
【0005】
【発明の実施の形態】
本発明経口用メラニン生成抑制組成物は、日焼けによるシミ・ソバカス、色黒等の発生並びに体質的な色素沈着を予防及び改善することを目的とした経口用組成物の形態で使用される。
本発明に用いるバラ及びキクは、その花弁は食用又は薬用としても既に使用されていて、服用しても毒性のないことは知られている。
本発明の抽出エキスの一つであるバラの抽出エキスは、バラ科バラ属に属する植物から抽出されるが、この植物から抽出したものであれば、茎、根、葉、花、種子のいずれからの抽出エキスであってもよい。
本発明のバラの抽出エキスは、バラ科バラ属(Rosa spp.)に属する植物から抽出されたエキスを使用することができる。例えば、ロサ・ガリカ(Rosa gallica)、ロサ・モスカタ(Rosa moschata)、ロサ・フォエティダ(Rosa foetida)、ロサ・ギガンテア(Rosa gigantea)、ノイバラ(Rosa multiflora)、テリハノイバラ(Rosa wichuraiana)等の野生種、またはこれらを交配して得られた園芸種の花、葉または茎を用いることができる。
本発明に用いる他の抽出エキスであるキクの抽出エキスは、キク科キク属に属する植物から抽出されるエキスであるが、この植物から抽出したものであれば、茎、根、葉、花、種子のいずれからの抽出エキスであってもよい。
本発明のキクの抽出エキスに用いる植物は、キク科キク属に属するキク(Chrisanthemum spp.)を使用することができる。例えば、イエギク(ショクヨウギク、Chrisanthemum morifolium)の花、葉または茎を用いることができる。
本発明組成物に用いる抽出エキスとしては、バラ抽出エキスの方法がキク抽出エキスよりも美白効果が優れている。
一般に植物から抽出エキスの抽出媒体としては、冷水、熱水、メタノールやエーテル等の有機溶媒、水と有機溶媒の混合溶媒などを使用することができる。
有機溶媒としては、通常抽出に使用する溶剤は制限なく使用でき、特に、アセトン、メタノール等の水溶性溶剤を使用することができ、また、これら有機溶剤と水との混合溶剤を使用することができる。
本発明の植物抽出エキスは、例えば次のような製造方法によって製造することができる。
植物試料をよく乾燥させた後、ミル等で細かくすり潰して粉砕し、70℃の熱水を用いて抽出する。抽出時間は、20〜60分程度であり、時間が長いほど収量が増加するが、60分を越えるとあまり増加しない。次いで、ガラスフィルターでろ過し固形物を取り除いた後、ろ液を減圧濃縮又は凍結乾燥を行ない熱水抽出凍結乾燥粉末エキス組成物若しくは濃縮エキスを得ることができる。
本発明の経口用メラニン生産抑制組成物は、バラあるいはキク抽出エキスの配合量は特に制限されないが、上記乾燥粉末組成物をそのまま薬剤のように粉剤、錠剤、シロップ剤又はカプセル剤の形状にして服用することができる。
また、水又は液状若しくは固体増量剤に添加した美白組成物として、服用することができる。この場合は、砂糖等の甘味料、香料、ビタミン又はクエン酸等の栄養剤を添加して、ドリンク剤として摂取することができる。
さらに、本発明組成物を、慣用の食品、例えば炭酸飲料、果実飲料、コーヒー、紅茶、牛乳、乳酸飲料、ヨーグルト、アイスクリーム、飴、ガム、菓子、パン、めん類等に混合して経口的に摂取することができる。この場合は、添加される慣用食品の風味を壊さない程度の添加量にするのが望ましい。
美白効果と風味との関係で、通常1〜50重量%、好ましくは10〜30重量%含有させることができる。
本発明の美白効果を得るためには、成人1日の摂取量は、前記濃縮エキスとして、0.05g以上、好ましくは1g以上を摂取するのが望ましい。本発明の組成物は、少量でも毎日の規則的摂取量に応じた美白効果があり、大量に摂取しても毒性がないので、可能な限り多量に摂取するほど美白効果が向上する。
体質的な色黒肌の場合は、最初は大量に服用して、美白効果が得られた後は、摂取量を減少させることができる。本発明組成物は副作用がないので、自由に摂取量を変更できる。
【0006】
【実施例】
以下の実施例によって本発明をさらに詳細に説明するが、本発明の範囲は、これらの実施例により限定されるものではない。
実施例1
洗浄後、1本のバラの樹木(茎、根、葉、花、種子を含む)を乾燥して得たバラ原料100gをミル等で細かく粉砕し、フラスコに入れ熱水1000mlを添加して、70℃の温度で撹拌しながら30分間抽出処理する。次いで、抽出処理物をガラスフィルターでろ過し、固形物を取り除き、ろ液を減圧濃縮によって、18.2gのバラ抽出濃縮エキスを得た。
参考例1
洗浄後、1本のキク樹木(茎、根、葉、花、種子を含む)を乾燥して得たキク原料100gをミル等で細かく粉砕し、熱水1000mlを添加し、70℃で撹拌しながら30分間抽出処理する。次いで抽出物をガラスフィルターで濾過し、固形物を取り除き、ろ液を凍結乾燥によって濃縮し、20.8gのキク抽出エキスを得た。
実施例3
培養したマウス由来のB16メラノーマ細胞から抽出したチロシナーゼ粗酵素液を用い、バラ抽出エキスとキク抽出エキスのチロシナーゼ活性阻害の測定を行なった。
なお、チロシナーゼ活性の測定は、基質であるL−DOPA(ジヒドロキシフェニルアラニン)からチロシナーゼにより生産されるドーパクロムを、490nmの吸光度測定によって定量する方法を用いた。ウエルプレート[FALCON社製]の13×100mmの試験管にバラ抽出エキスあるいはキク抽出エキスを入れ、PBS緩衝液で溶解した1mML−DOPA(ジヒドロキシフェニルアラニン)1mlとチロシナーゼ粗酵素液0.05mlを添加した。最終濃度は、抽出エキスが1.2、0.8、0.4%となるようにした。37℃で30分間インキュベーション後、分光光度計を用いて490nmの吸光度を測定した。対照群(PBS緩衝液のみ)の吸光度に対する比率を算出して、試料のチロシナーゼ活性阻害率とした。結果を第1表に示した。
【0007】
【表1】

Figure 0003818483
【0008】
第1表からもわかるように、バラ抽出エキス及びキク抽出エキスは、濃度依存的にチロシナーゼ活性抑制作用を有することが確認された。
実施例4
マウス由来のB16メラノーマ細胞を使用し、細胞白色化効果の評価を行った。メラノーマ細胞を直径10cmの培養皿内に1×105個/皿の密度でまき、そしてウシ胎児血清を10%含むダルベッコ変法イーグル培地を使用して37℃において24時間培養した。その後、バラ抽出エキスあるいはキク抽出エキスをその培地中濃度が1%、0.5%、および0.2%となるように添加し、さらに6日間培養した。対照として、生理食塩水を添加したものを用いた。培養終了後、該培地を捨てて各ウエルプレートに1mlの生理食塩水を加え、スクレーパーを用いてウエルの底面に付着している細胞をかきとるように懸濁させた。次にピペットを用いて該細胞懸濁液をマイクロ遠心チューブ[1.5ml容量、エッペンドルフ社製]に移し、遠心分離(1000G、15分間)した。次に、ペレットとなった細胞の白色化の度合いを目視で比較し、メラニン生成抑制効果の判定を行った。その際、対照群の細胞の白色化度合を±とし、これよりやや白色の場合は+、これよりはっきりと白色の度合が強い場合を++として、3段階の判定を行った。なおその結果は第2表に示した。
【0009】
【表2】
Figure 0003818483
【0010】
第2表からもわかるように、バラ抽出エキス及びキク抽出エキスは、濃度が大きいほどメラニン生成抑制作用を有することが確認された。
この試験方法における細胞白色化効果は経皮的に塗布する方法の美白効果に密接に関係する。従って、経皮的な塗布方法による場合は、キク抽出エキスの方がバラ抽出エキスよりも美白効果があると認められる。
実施例5
PUVA処置により有色モルモットA−1を用いたバラ抽出エキス、キク抽出エキスの表皮内チロシナーゼ活性阻害効果について検討した。本試験に使用した有色モルモットA−1は、English系の有色モルモットJY−8とハートレー系アルビノモルモットとの交配種であり、シナモン色の被毛を持つ。4週齢の雄性該被験動物(体重60g)に、バラ抽出エキスあるいはキク抽出エキスの10%水溶液、5%水溶液、および1%水溶液を1日当り5ml経口投与し、2週間飼育した。対照はバラ抽出エキスあるいはキク抽出エキスの代りに水を投与し、同様に2週間飼育した。その後、背部被毛をバリカンとシェーバーで剃毛した後、外科的に2×2cmの正方形の皮膚を採取し、ディスパーゼに浸すことにより表皮を剥離した。2mlのPBS中でホモジナイズし、チロシナーゼ活性測定用の試料とした。この試料0.05mlを1mlの1mML−DOPA溶液中に添加し、37℃で30分間インキュベート後、分光光度計を用いて490nmの吸光度を測定した。対照群の吸光度に対する比率を算出して、試料のチロシナーゼ活性阻害率とした。結果を第3表に示した。有色モルモットの肌の褪色の有無は対照との対比で、色の褪色が目視観察で感知できるものを「有」とした。
【0011】
【表3】
Figure 0003818483
【0012】
第3表からもわかるように、バラ抽出エキス及びキク抽出エキスは、経口投与において投与量に依存して、表皮のチロシナーゼ活性を阻害することが確認された。これは2週間の摂取期間であるので、長期にわたって常用する場合は、人間に対する1日の摂取量は、50mg以上と考えられる。
本実施例の結果は、経口的に摂取した場合の美白効果に対応するものである。本実施例の結果は、経口的に摂取した場合は、美白作用効果はバラ抽出エキスの方が優れていて、実施例4の経皮的摂取の場合と逆転していることを示している。
実施例6
実施例1で得たバラ抽出濃縮エキスを用いて、次の処方で風味が良好な飲料を製造した。
水 40g
バラ抽出濃縮エキス 100mg
果糖ブドウ糖液糖 10g
クエン酸 250mg
ビタミンC 50mg
クエン酸三ナトリウム 50mg
香料 10mg
【0013】
【発明の効果】
本発明は、経口的に摂取する美白組成物によって、副作用がなく、全身的美白効果及び発汗及び摩擦によって影響されない美白効果を得ることを可能としたものであり、美白美容方法にとって有用な発明である。さらに、季節的な日焼け防止効果のみならず、体質的なメラニン発生防止(体質的色黒肌の褪色)を得るために、長期間の服用によっても副作用がない利点がある。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an oral melanin production-suppressing composition containing a rose or chrysanthemum extract as an active ingredient, and a food containing the composition.
[0002]
[Prior art]
In general, blackish-colored spots, spots, buckwheat, and the like caused by sunburn are caused by the production of melanin, which is a black-brown amorphous pigment. In addition, people who are born with dark skin are also considered to have a high constitution of melanin.
Physiologically, the cause of the formation of melanin in the skin has not yet been fully elucidated, but as one of the causes, melanocytes that produce melanin in the skin when the skin is subjected to external stimuli such as ultraviolet rays The mechanism by which tyrosinase (tyrosine oxidase) present in the cells is activated and tyrosine, a kind of protein-constituting amino acid, is oxidized and produced has been elucidated. It can be presumed that a person who is dark in color is sensitive to the activation of tyrosinase.
From this, since the effect of whitening the skin is expected by suppressing the activity of tyrosinase involved in melanin production, the formulation of a tyrosinase activity-suppressing ingredient in cosmetics has been proposed.
From such a viewpoint, as an inhibitor of stains and freckles, in addition to ultraviolet absorbers, reducing agents such as ascorbic acid and hydroquinone derivatives, tyrosinase inhibitors such as kojic acid and linoleic acid (Japanese Patent Laid-Open No. 63-284109) JP-A-1-85907), whitening agents mainly composed of catechol glycosides (see JP-A4-1115), whitening agents mainly composed of flavonoids (JP-A-55- No. 92305), whitening agent containing isoferulic acid as a main component (see JP-A-62-210312), whitening agent containing azelaic acid as a main component (see JP-A-61-85307) Etc. have been developed.
On the other hand, whitening cosmetics containing a herbal extract derived from a rose family plant (see Japanese Patent Laid-Open No. 3-127714), and whitening cosmetics containing an extract of a rose family plant (Japanese Patent Laid-Open No. 9-227353). However, these are all external preparations for skin, and an oral whitening melanin production inhibiting composition is not known.
[0003]
[Problems to be solved by the invention]
All of the above-mentioned prior art whitening agents are external preparations for skin, and in the case of external preparations for skin, since the whitening effect can be expected only from the applied local part, it is recommended for those who need a general whitening effect. Was insufficient. Furthermore, even in the case of a person who desires a partial whitening effect such as a face with high interest in cosmetics, the effect may be reduced or disappeared by sweating or physical frictional action, and must be applied every short time. So it was inconvenient.
An object of the present invention is to provide a whitening means that has no side effects even if it is regularly used, has a general whitening effect, and does not deteriorate the whitening effect due to sweating and friction.
[0004]
[Means for Solving the Problems]
The inventors of the present invention pay attention to the disadvantages of conventional whitening agents that are caused by application to the skin, and if they are taken orally and find what has a whitening effect, these disadvantages are Focusing on the fact that it can be solved simultaneously, as a result of earnestly researching those that are not toxic even if taken and have effective effects even if taken, among those that have been effective transcutaneously, rose and chrysanthemum It has been found that even if the extract of this is taken orally, it has a remarkable melanin production inhibitory effect, and based on this finding, the present invention has been completed.
That is, the present invention provides an oral melanin production-suppressing composition containing as an active ingredient a dry powder composition obtained by concentrating an extract of roses (but excluding tie vana rose).
[0005]
DETAILED DESCRIPTION OF THE INVENTION
The oral melanin production-suppressing composition of the present invention is used in the form of an oral composition for the purpose of preventing and improving the occurrence of spots, freckles, darkness, etc. and physical pigmentation due to sunburn.
The roses and chrysanthemums used in the present invention are known to have no petals in their edible or medicinal uses and are not toxic when taken.
The rose extract, which is one of the extract extracts of the present invention, is extracted from a plant belonging to the genus Rosaceae, and any one of stems, roots, leaves, flowers and seeds can be extracted from this plant. It may be an extract from
As the rose extract of the present invention, an extract extracted from a plant belonging to the genus Rosa spp. Can be used. For example, wild species such as Rosa gallica, Rosa moschata, Rosa foetida, Rosa gigantea, Rosa multiflora, Rosa wichuraiana, Or flowers, leaves or stems of horticultural species obtained by crossing these can be used.
The extract of chrysanthemum, which is another extract used in the present invention, is an extract extracted from a plant belonging to the genus Chrysanthemum, but if extracted from this plant, stem, root, leaf, flower, It may be an extract from any of the seeds.
As a plant used for the extract of chrysanthemum of the present invention, chrysanthemum spp. Belonging to the genus Asteraceae can be used. For example, flowers, leaves or stems of yellow daisy (Chrysanthemum morifolium) can be used.
As an extract used in the composition of the present invention, the rose extract method is superior in whitening effect to chrysanthemum extract.
In general, cold water, hot water, an organic solvent such as methanol or ether, a mixed solvent of water and an organic solvent, or the like can be used as an extraction medium for an extract extracted from a plant.
As the organic solvent, a solvent usually used for extraction can be used without limitation, and in particular, a water-soluble solvent such as acetone or methanol can be used, and a mixed solvent of these organic solvent and water can be used. it can.
The plant extract of the present invention can be produced, for example, by the following production method.
After thoroughly drying the plant sample, it is finely ground and pulverized with a mill or the like, and extracted with hot water at 70 ° C. The extraction time is about 20 to 60 minutes, and the longer the time, the higher the yield. However, when the time exceeds 60 minutes, the extraction time does not increase much. Next, after filtering through a glass filter to remove solids, the filtrate is concentrated under reduced pressure or freeze-dried to obtain a hot water extraction freeze-dried powder extract composition or concentrated extract.
In the composition for inhibiting melanin production for oral use of the present invention, the amount of rose or chrysanthemum extract is not particularly limited, but the dry powder composition can be used in the form of a powder, tablet, syrup or capsule like a medicine. Can be taken.
It can also be taken as a whitening composition added to water or liquid or solid extenders. In this case, sweeteners such as sugar, fragrances, vitamins, or nutrients such as citric acid can be added and ingested as a drink.
Furthermore, the composition of the present invention is orally mixed with conventional foods such as carbonated drinks, fruit drinks, coffee, tea, milk, lactic acid drinks, yogurt, ice cream, rice cake, gum, confectionery, bread, noodles and the like. Can be ingested. In this case, it is desirable to make the addition amount so as not to break the flavor of the conventional food to be added.
Due to the relationship between the whitening effect and the flavor, it is usually 1 to 50% by weight, preferably 10 to 30% by weight.
In order to obtain the whitening effect of the present invention, the daily intake for adults is preferably 0.05 g or more, preferably 1 g or more, as the concentrated extract. The composition of the present invention has a whitening effect according to the regular daily intake even in a small amount, and since it is not toxic even when ingested in a large amount, the whitening effect improves as it is ingested as much as possible.
In the case of constitutional dark skin, take a large amount at first, and after the whitening effect is obtained, the intake can be reduced. Since the composition of the present invention has no side effects, the intake can be freely changed.
[0006]
【Example】
The present invention will be described in more detail by the following examples, but the scope of the present invention is not limited by these examples.
Example 1
After washing, 100 g of rose raw material obtained by drying one rose tree (including stem, root, leaf, flower, seed) is finely pulverized with a mill or the like, put into a flask, and 1000 ml of hot water is added. Extraction is performed for 30 minutes while stirring at a temperature of 70 ° C. Next, the extracted product was filtered through a glass filter to remove solids, and the filtrate was concentrated under reduced pressure to obtain 18.2 g of rose extract concentrated extract.
Reference example 1
After washing, 100 g chrysanthemum raw material obtained by drying one chrysanthemum tree (including stems, roots, leaves, flowers, and seeds) is finely pulverized with a mill or the like, added with 1000 ml of hot water, and stirred at 70 ° C. Extract for 30 minutes. The extract was then filtered through a glass filter to remove solids and the filtrate was concentrated by lyophilization to yield 20.8 g chrysanthemum extract.
Example 3
Using the tyrosinase crude enzyme solution extracted from cultured mouse-derived B16 melanoma cells, the inhibition of tyrosinase activity of the rose extract and chrysanthemum extract was measured.
The tyrosinase activity was measured by a method in which dopachrome produced by tyrosinase from L-DOPA (dihydroxyphenylalanine) as a substrate was quantified by measuring absorbance at 490 nm. A rose extract or chrysanthemum extract was placed in a 13 × 100 mm test tube of a well plate (manufactured by FALCON), and 1 ml of 1 mM L-DOPA (dihydroxyphenylalanine) dissolved in PBS buffer and 0.05 ml of tyrosinase crude enzyme solution were added. . The final concentration was adjusted so that the extracted extract was 1.2, 0.8, and 0.4%. After incubation at 37 ° C. for 30 minutes, absorbance at 490 nm was measured using a spectrophotometer. The ratio of the control group (PBS buffer only) to the absorbance was calculated and used as the tyrosinase activity inhibition rate of the sample. The results are shown in Table 1.
[0007]
[Table 1]
Figure 0003818483
[0008]
As can be seen from Table 1, it was confirmed that the rose extract and chrysanthemum extract have a tyrosinase activity inhibitory effect in a concentration-dependent manner.
Example 4
B16 melanoma cells derived from mice were used to evaluate the cell whitening effect. Melanoma cells were seeded at a density of 1 × 10 5 cells / dish in a 10 cm diameter culture dish and cultured at 37 ° C. for 24 hours using Dulbecco's modified Eagle medium containing 10% fetal calf serum. Thereafter, rose extract or chrysanthemum extract was added so that the concentration in the medium would be 1%, 0.5%, and 0.2%, and further cultured for 6 days. As a control, a solution supplemented with physiological saline was used. After completion of the culture, the medium was discarded, 1 ml of physiological saline was added to each well plate, and the cells adhering to the bottom of the well were scraped using a scraper. Next, the cell suspension was transferred to a microcentrifuge tube [1.5 ml volume, manufactured by Eppendorf] using a pipette, and centrifuged (1000 G, 15 minutes). Next, the degree of whitening of the pelleted cells was compared visually to determine the melanin production inhibitory effect. At that time, the degree of whitening of the cells in the control group was defined as ±, and when it was slightly whiter than this, it was judged as +, and when it was clearly whiter than ++, it was judged in three stages. The results are shown in Table 2.
[0009]
[Table 2]
Figure 0003818483
[0010]
As can be seen from Table 2, it was confirmed that the rose extract and chrysanthemum extract have a melanin production inhibitory effect as the concentration increases.
The cell whitening effect in this test method is closely related to the whitening effect of the transdermal application method. Therefore, when the transdermal application method is used, it is recognized that the chrysanthemum extract has a whitening effect than the rose extract.
Example 5
The inhibitory effect of the rose extract and chrysanthemum extract using colored guinea pig A-1 by the PUVA treatment on the epidermal tyrosinase activity was examined. The colored guinea pig A-1 used in this test is a hybrid of an English colored guinea pig JY-8 and a Hartley albino guinea pig and has cinnamon-colored hair. Four-week-old male test animals (body weight 60 g) were orally administered with 10 ml aqueous solution, 5% aqueous solution, and 1% aqueous solution of rose extract or chrysanthemum extract per day, and were bred for 2 weeks. As a control, water was administered instead of the rose extract or chrysanthemum extract, and the animals were similarly raised for 2 weeks. Thereafter, the back coat was shaved with a clipper and a shaver, and then a 2 × 2 cm square skin was surgically collected, and the epidermis was peeled off by immersing in dispase. The sample was homogenized in 2 ml of PBS and used as a sample for measuring tyrosinase activity. 0.05 ml of this sample was added to 1 ml of 1 mM L-DOPA solution, incubated at 37 ° C. for 30 minutes, and then the absorbance at 490 nm was measured using a spectrophotometer. The ratio of the control group to the absorbance was calculated and used as the tyrosinase activity inhibition rate of the sample. The results are shown in Table 3. The presence or absence of the fading color of the colored guinea pig skin was compared with the control.
[0011]
[Table 3]
Figure 0003818483
[0012]
As can be seen from Table 3, rose extract and chrysanthemum extract were confirmed to inhibit epidermal tyrosinase activity depending on the dose in oral administration. Since this is an intake period of 2 weeks, the daily intake for humans is considered to be 50 mg or more when used regularly over a long period of time.
The results of this example correspond to the whitening effect when taken orally. The results of this example indicate that when taken orally, the whitening effect is superior to the rose extract, which is the reverse of the transdermal intake of Example 4.
Example 6
Using the rose extract concentrated extract obtained in Example 1, a beverage with good flavor was produced according to the following formulation.
40g of water
Rose extract concentrate 100mg
Fructose dextrose liquid sugar 10g
Citric acid 250mg
Vitamin C 50mg
Trisodium citrate 50mg
Fragrance 10mg
[0013]
【The invention's effect】
The present invention makes it possible to obtain a whitening effect that is free from side effects and is not affected by sweating and friction by a whitening composition that is taken orally, and is useful for a whitening beauty method. is there. Furthermore, in order to obtain not only a seasonal sunburn preventing effect but also a constitutional prevention of melanin generation (a discoloration of constitutional black skin), there is an advantage that there are no side effects even when taken for a long time.

Claims (1)

バラ(ただし、タイワンノイバラを除く)の抽出液を濃縮した乾燥粉末組成物を有効成分として含有する経口用メラニン生成抑制組成物。An oral melanin production-suppressing composition comprising as an active ingredient a dry powder composition obtained by concentrating an extract of roses (but excluding Thai one rose).
JP21931399A 1999-08-02 1999-08-02 Oral melanin production inhibiting composition and food having whitening effect Expired - Fee Related JP3818483B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP21931399A JP3818483B2 (en) 1999-08-02 1999-08-02 Oral melanin production inhibiting composition and food having whitening effect

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP21931399A JP3818483B2 (en) 1999-08-02 1999-08-02 Oral melanin production inhibiting composition and food having whitening effect

Publications (3)

Publication Number Publication Date
JP2001048801A JP2001048801A (en) 2001-02-20
JP2001048801A5 JP2001048801A5 (en) 2005-11-04
JP3818483B2 true JP3818483B2 (en) 2006-09-06

Family

ID=16733538

Family Applications (1)

Application Number Title Priority Date Filing Date
JP21931399A Expired - Fee Related JP3818483B2 (en) 1999-08-02 1999-08-02 Oral melanin production inhibiting composition and food having whitening effect

Country Status (1)

Country Link
JP (1) JP3818483B2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4233734B2 (en) * 2000-07-19 2009-03-04 株式会社資生堂 Skin external preparation for whitening
JP4659378B2 (en) * 2004-03-30 2011-03-30 株式会社東洋発酵 Melanin production inhibitor, and cosmetic materials, cosmetics, food and beverage additives, foods and beverages, and bath agents containing the melanin production inhibitor
CN102573787A (en) * 2009-08-14 2012-07-11 株式会社爱茉莉太平洋 Composition containing a natural extract
JP5690149B2 (en) * 2011-01-18 2015-03-25 日本メナード化粧品株式会社 External preparation or internal preparation
JP6333057B2 (en) * 2014-05-15 2018-05-30 白井松新薬株式会社 Tyrosinase inhibitor and method for producing the same
JP6378968B2 (en) * 2014-08-19 2018-08-22 株式会社山田養蜂場本社 Whitening composition
CN116751636A (en) * 2023-07-03 2023-09-15 海南玫瑰谷产业发展有限公司 Method for extracting rose essential oil from rose dreg

Also Published As

Publication number Publication date
JP2001048801A (en) 2001-02-20

Similar Documents

Publication Publication Date Title
US20210330575A1 (en) Cosmetic composition for skin whitening and wrinkle improvement comprising adventitious root extract of centella asiatica as effective ingredient
US8394426B2 (en) Composition comprising an extract of hardy kiwi for preventing or treating baldness disorders or seborrheic skin disorders
EP1793792A1 (en) Composition comprising the extract of actinidia arguta for preventing and treating baldness disorders and seborrheic skin disorders
JP3818483B2 (en) Oral melanin production inhibiting composition and food having whitening effect
KR102442861B1 (en) Composition for skin whitening and Pharmaceutical composition for use in preventing or treating disorders of Melanin Hyperpigmentation containing Pediococcus acidilactici PMC48 strain a culture medium thereof as an active ingredient
KR101453258B1 (en) Health Functional Food Composition Comprising Red Ginseng Extract, Benincasa Hispida Extract, and Apios Americana Extract for Improving Skin Beauty
KR101429117B1 (en) Composition for skin-whitening comprising extract of calyx of peach blossom
JP2003171300A (en) Melanization inhibitor
KR101512811B1 (en) Cosmetic Composition Comprising Reynoutria japonica for. elata Extract for Skin Whitening
KR101943976B1 (en) Composition for skin whitening comprising Capsicum annuum seed extract as effective component
KR20190077156A (en) Cosmetic composition for skin whitening and moisturizing comprising larva extract of Protaetia brevitarsis as effective component
KR102471009B1 (en) Cosmetic composition containing Albiggia kalkora extract for skin whitening and improving wrinkles
KR102154139B1 (en) Composition comprising fermentation of sap of painted maple, cacao nibs extract and granat extract
JP2017521411A (en) Whitening composition containing Scutellaria alpina extract
KR20220077991A (en) Composition for anti-inflammation and anti-wrinkle comprising fermentative product of Gryllus bimaculatus extract as effective component
KR20210069823A (en) Fermented Extract of Panax Sprout for Whitening Cosmetics
KR101761142B1 (en) Skin-lightening Composition Using an Extract of Rumex acetosella
JP6574436B2 (en) Composition containing alpine wormwood extract
JP4902967B2 (en) Melanin production inhibitor
KR101889492B1 (en) composition containing complex extract of Morus alba for pendula, Prunus salicina and Oenothera lamarckiana
KR20200073851A (en) Composition for skin-whitening comprising Amaranth extracts
KR102226346B1 (en) Compositon comprising fermented product of Cynanchi atrati Radix as an active ingredient for skin whitening
KR20190120860A (en) Cosmetic compostion including extracts of fig leaves
KR102644047B1 (en) A composition for preventing or improving skin wrinkles or skin thermal aging comprising rosa multiflora extracts
KR102613802B1 (en) Composition for skin whitening comprising culture of Lactobacillus reuteri and extract of Cnidium Monnieri

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050909

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20050909

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20051005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051018

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051219

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060526

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060608

R150 Certificate of patent or registration of utility model

Ref document number: 3818483

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090623

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100623

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100623

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110623

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120623

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120623

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130623

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140623

Year of fee payment: 8

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees